Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly’s profit doubled in the fourth quarter ... Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while ...